Table 2.

Plasma KIM-1 and the risk of adverse clinical outcomes in the BKBC Study.

Plasma KIM-1	Events	Events per 100 person-years	Model 1	p-value	Model 2	p-value	Model 3	p-value
Kidney Failure
Tertile 1	19	2.1	Reference		Reference		Reference
Tertile 2	37	5.4	2.39 (1.35 – 4.22)	0.003	2.35 (1.30 – 4.27)	0.005	1.40 (0.77 – 2.56)	0.3
Tertile 3	68	12.3	5.12 (3.00 – 8.73)	<0.001	4.62 (2.57 – 8.32)	<0.001	1.46 (0.80 – 2.64)	0.2
Continuous, per doubling KIM-1	124	5.8	1.66 (1.48 – 1.87)	<0.001	1.65 (1.43 – 1.90)	<0.001	1.19 (1.03 – 1.38)	0.02
Mortality
Tertile 1	12	1.2	Reference		Reference		Reference
Tertile 2	31	3.6	2.17 (1.09 – 4.29)	0.03	1.93 (0.96 – 3.90)	0.07	1.46 (0.72 – 2.96)	0.3
Tertile 3	42	5.0	2.92 (1.51 – 5.68)	0.002	2.63 (1.30 – 5.34)	0.007	1.48 (0.69 – 3.18)	0.3
Continuous, per doubling KIM-1	85	3.1	1.25 (1.09 – 1.43)	0.001	1.23 (1.06 – 1.44)	0.008	1.05 (0.89 – 1.25)	0.6

Results are expressed as hazard ratios (95% CI); Kidney failure, defined as initiation of kidney replacement therapy.

Model 1 is stratified by site and adjusted for age, sex, and race.

Model 2 is model 1 and further adjusts natural log transformed proteinuria, primary clinicopathologic diagnosis, ACEi/ARB use, and immunosuppression/corticosteroids.

Model 3 is model 2 and further adjusts for eGFR

Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate